Regencell Bioscience (NASDAQ:RGC) Shares Down 10.1% – Here’s What Happened

Regencell Bioscience Holdings Limited (NASDAQ:RGC)’s stock price traded down 10.1% on Thursday . The company traded as low as $25.51 and last traded at $25.51. 64,302 shares were traded during mid-day trading, a decline of 92% from the average session volume of 846,394 shares. The stock had previously closed at $28.38.

Analysts Set New Price Targets

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Regencell Bioscience in a research report on Monday, December 29th. One analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the company has a consensus rating of “Sell”.

Regencell Bioscience Price Performance

The stock’s fifty day simple moving average is $24.57 and its 200-day simple moving average is $18.04.

Institutional Trading of Regencell Bioscience

Several large investors have recently bought and sold shares of RGC. Geode Capital Management LLC raised its stake in shares of Regencell Bioscience by 5,637.5% during the 2nd quarter. Geode Capital Management LLC now owns 391,066 shares of the company’s stock worth $6,664,000 after buying an additional 384,250 shares during the last quarter. Squarepoint Ops LLC acquired a new position in Regencell Bioscience during the second quarter worth about $1,701,000. BNP Paribas Financial Markets acquired a new position in Regencell Bioscience during the second quarter worth about $768,000. XTX Topco Ltd purchased a new stake in shares of Regencell Bioscience in the third quarter valued at about $598,000. Finally, Y Intercept Hong Kong Ltd acquired a new stake in shares of Regencell Bioscience in the second quarter valued at approximately $222,000. Institutional investors and hedge funds own 0.13% of the company’s stock.

Regencell Bioscience Company Profile

Regencell Bioscience Holdings Limited operates a Traditional Chinese medicine (TCM) bioscience company. It focuses on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degeneration, primarily attention deficit hyperactivity disorder and autism spectrum disorder. The company was incorporated in 2014 and is headquartered in Causeway Bay, Hong Kong.